Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

1.6K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic performance and interchangeability of two commercial anti-RSV-IgG and IgA ELISAs across clinically relevant populations.

Microbiology spectrum·2026
Same author

Stress granule phase separation in stress-responsive cytosolic extract-in-oil droplets.

Nature communications·2026
Same author

Deprescribing of proton pump inhibitors in internal medicine in-patients: A retrospective observational study.

Exploratory research in clinical and social pharmacy·2026
Same author

Quantifying diclofenac - proven in theory, problematic in practice.

Bioanalysis·2026
Same author

Referral pathway for adults with chronic cough in Switzerland from a Delphi-based consensus study.

Postgraduate medicine·2026
Same author

Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-up.

Research and practice in thrombosis and haemostasis·2026

Related Experiment Video

Updated: Nov 23, 2025

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.8K

Leucopenia associated with metamizole: a case-control study.

Lea Blaser1, Hala Hassna1, Sarah Hofmann1

  • 1Division of Clinical Pharmacology and Toxicology, University and University Hospital Basel, Switzerland.

Swiss Medical Weekly
|December 30, 2020
PubMed
Summary

Metamizole use can lead to leucopenia. Risk factors include allergies, prior leucopenic episodes, hepatitis C, and concurrent cytostatic agents, aiding in prevention strategies.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.4K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

20.8K

Related Experiment Videos

Last Updated: Nov 23, 2025

Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.8K
Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

9.4K
A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model
08:00

A Detailed Protocol for Characterizing the Murine C1498 Cell Line and its Associated Leukemia Mouse Model

Published on: October 14, 2016

20.8K

Area of Science:

  • Pharmacovigilance
  • Hematology
  • Infectious Diseases

Background:

  • Metamizole is a widely used analgesic and antipyretic.
  • Leucopenia is a potential adverse drug reaction associated with metamizole.
  • Identifying risk factors is crucial for patient safety.

Purpose of the Study:

  • To investigate potential risk factors for leucopenia in patients using metamizole.
  • To compare characteristics of patients who developed leucopenia with those who did not.

Main Methods:

  • A retrospective case-control study design was employed.
  • Cases of metamizole-associated leucopenia were identified and compared to matched controls.
  • Data collection included patient history, comorbidities, and concomitant medications.

Main Results:

  • A history of allergies and previous leucopenic episodes were significantly associated with metamizole-induced leucopenia.
  • Hepatitis C infection prevalence was higher in cases (9%) than controls (1%).
  • Concomitant use of cytostatic agents was a significant risk factor in non-postoperative cases.

Conclusions:

  • Allergies, prior leucopenia, hepatitis C, and concurrent cytostatic agents are identified as potential risk factors.
  • These findings can inform clinical practice and patient monitoring.
  • Further research may elucidate underlying mechanisms.